The Shanghai provider of outsourced drug-research services agrees to be acquired for $21.25 a share, or $1.6 billion, of cash and stock by Charles River Laboratories.
http://digg.com/u1USG3
The Shanghai provider of outsourced drug-research services agrees to be acquired for $21.25 a share, or $1.6 billion, of cash and stock by Charles River Laboratories.
No comments:
Post a Comment